CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Country • United States
    Entity • country not supported, please select another country
    English العَرَبِيَّة Bahasa Indonesia Български Čeština Dansk Deutsch Eesti ελληνικά Español Français Hrvatski Italiano Latviešu Lietuvių Magyar Nederlands Polski Português Română Русский Slovenčina Slovenščina Suomi Svenska Tiếng Việt ไทย 简体中文 繁體中文

    Trade Cytori Therapeutics - PSTV CFD

    0.37
    2.63%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.06
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.024874 %
    Charges from borrowed part ($-0.99)
    Trade size with leverage ~ $5,000.00
    Money from leverage ~ $4,000.00
    Go to platform
    		-0.024874%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.002651 %
    Charges from borrowed part ($0.11)
    Trade size with leverage ~ $5,000.00
    Money from leverage ~ $4,000.00
    Go to platform
    		0.002651%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 20%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Key Stats
    Prev. Close* 0.38
    Open* 0.38
    1-Year Change* -60%
    Day's Range* 0.37 - 0.38
    52 wk Range 0.25-1.20
    Average Volume (10 days) 253.72K
    Average Volume (3 months) 6.61M
    Market Cap 9.48M
    P/E Ratio -100.00K
    Shares Outstanding 35.42M
    Revenue 224.00K
    EPS -0.79
    Dividend (Yield %) N/A
    Beta 0.40
    Next Earnings Date Apr 19, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Feb 23, 2023 0.37 -0.01 -2.63% 0.38 0.38 0.37
    Feb 22, 2023 0.38 0.00 0.00% 0.38 0.38 0.38
    Feb 8, 2023 0.37 -0.01 -2.63% 0.38 0.38 0.37
    Feb 6, 2023 0.38 -0.01 -2.56% 0.39 0.39 0.38
    Feb 3, 2023 0.39 0.00 0.00% 0.39 0.39 0.39
    Feb 2, 2023 0.39 0.00 0.00% 0.39 0.40 0.38
    Feb 1, 2023 0.38 -0.04 -9.52% 0.42 0.42 0.38
    Jan 31, 2023 0.40 -0.02 -4.76% 0.42 0.42 0.39
    Jan 30, 2023 0.43 0.01 2.38% 0.42 0.44 0.42
    Jan 27, 2023 0.42 0.01 2.44% 0.41 0.42 0.40
    Jan 26, 2023 0.41 0.00 0.00% 0.41 0.42 0.41
    Jan 25, 2023 0.41 0.01 2.50% 0.40 0.42 0.40
    Jan 24, 2023 0.41 0.00 0.00% 0.41 0.41 0.41
    Jan 23, 2023 0.41 -0.01 -2.38% 0.42 0.43 0.41
    Jan 20, 2023 0.41 -0.01 -2.38% 0.42 0.43 0.40
    Jan 19, 2023 0.42 0.01 2.44% 0.41 0.42 0.40
    Jan 18, 2023 0.42 -0.03 -6.67% 0.45 0.45 0.40
    Jan 17, 2023 0.45 0.00 0.00% 0.45 0.45 0.43
    Jan 13, 2023 0.45 0.07 18.42% 0.38 0.45 0.38
    Jan 9, 2023 0.38 0.00 0.00% 0.38 0.38 0.38

    Cytori Therapeutics Events

    Time (UTC) Country Event
    No events scheduled
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 0.224 0 0.303 6.998 6.654
    Revenue 0.224 0 0.303 6.998 6.654
    Cost of Revenue, Total 2.373
    Gross Profit 4.281
    Total Operating Expense 19.936 12.492 9.887 10.655 19.352
    Selling/General/Admin. Expenses, Total 10.238 6.853 6.406 5.29 8.357
    Research & Development 9.698 5.323 2.7 5.365 8.622
    Interest Expense (Income) - Net Operating
    Unusual Expense (Income) 0 0.316 0.781 0
    Operating Income -19.712 -12.492 -9.584 -3.657 -12.698
    Interest Income (Expense), Net Non-Operating -0.563 -0.907 1.343 1.607 0.354
    Other, Net 0 -1.233 -0.29
    Net Income Before Taxes -20.275 -13.399 -8.241 -3.283 -12.634
    Net Income After Taxes -20.275 -13.399 -8.241 -3.283 -12.634
    Net Income Before Extra. Items -20.275 -13.399 -8.241 -3.283 -12.634
    Net Income -20.275 -13.399 -8.241 -10.887 -12.634
    Total Adjustments to Net Income 0 -0.554 -2.487
    Income Available to Common Excl. Extra. Items -20.275 -13.399 -8.241 -3.837 -15.121
    Income Available to Common Incl. Extra. Items -20.275 -13.399 -8.241 -11.441 -15.121
    Diluted Net Income -20.275 -13.399 -8.241 -11.441 -15.121
    Diluted Weighted Average Shares 26.2553 12.0892 4.42784 1.38401 0.17385
    Diluted EPS Excluding Extraordinary Items -0.77223 -1.10835 -1.86118 -2.77237 -86.9768
    Diluted Normalized EPS -0.77223 -1.08221 -1.6848 -2.77237 -86.9768
    Total Extraordinary Items 0 -7.604
    Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021
    Total revenue 0.151 0.073 0 0 0
    Revenue 0.151 0.073 0
    Total Operating Expense 5.723 5.167 5.12 3.926 3.939
    Selling/General/Admin. Expenses, Total 3.585 2.222 2.289 2.141 2.042
    Research & Development 2.138 2.945 2.831 1.785 1.599
    Operating Income -5.572 -5.094 -5.12 -3.926 -3.939
    Interest Income (Expense), Net Non-Operating -0.086 -0.125 -0.162 -0.19 -0.216
    Net Income Before Taxes -5.658 -5.219 -5.282 -4.116 -4.155
    Net Income After Taxes -5.658 -5.219 -5.282 -4.116 -4.155
    Net Income Before Extra. Items -5.658 -5.219 -5.282 -4.116 -4.155
    Net Income -5.658 -5.219 -5.282 -4.116 -4.155
    Income Available to Common Excl. Extra. Items -5.658 -5.219 -5.282 -4.116 -4.155
    Income Available to Common Incl. Extra. Items -5.658 -5.219 -5.282 -4.116 -4.155
    Diluted Net Income -5.658 -5.219 -5.282 -4.116 -4.155
    Diluted Weighted Average Shares 33.6534 27.4417 22.2548 21.5071 15.4729
    Diluted EPS Excluding Extraordinary Items -0.16813 -0.19019 -0.23734 -0.19138 -0.26853
    Dividends per Share - Common Stock Primary Issue 0 0 0
    Diluted Normalized EPS -0.16813 -0.19019 -0.23734 -0.19138 -0.24927
    Unusual Expense (Income) 0 0 0.298
    • Annual
    • Quarterly
    2021 2020 2019 2018 2017
    Total Current Assets 19.724 9.175 19.825 9.648 14.864
    Cash and Short Term Investments 18.4 8.346 17.552 5.261 9.55
    Cash & Equivalents 18.4 8.346 17.552 5.261 9.55
    Total Receivables, Net 0 1.313 0.178 0.145
    Accounts Receivable - Trade, Net 0 1.169 0.178 0.145
    Total Inventory 0 0.107 0.107 3.183
    Other Current Assets, Total 0.007 0.059 0.04 4.102 1.986
    Total Assets 21.981 12.105 23.229 23.991 31.615
    Property/Plant/Equipment, Total - Net 1.818 2.456 2.96 2.299 3.052
    Goodwill, Net 0.372 0.372 0.372 0.372 3.922
    Intangibles, Net 0.051 0.086 7.207
    Other Long Term Assets, Total 0.016 0.016 0.072 11.672 2.57
    Total Current Liabilities 5.87 8.539 14.486 17.559 18.414
    Payable/Accrued 0.245 2.777 4.79
    Notes Payable/Short Term Debt 1.608 6.335 0 14.202 13.624
    Current Port. of LT Debt/Capital Leases 0 0.01 11.18
    Total Liabilities 11.145 9.074 22.069 18.766 18.615
    Total Long Term Debt 5.005 0 0.008 0 0
    Long Term Debt 5.005 0
    Other Liabilities, Total 0.27 0.535 7.575 1.207 0.201
    Total Equity 10.836 3.031 1.16 5.225 13
    Preferred Stock - Non Redeemable, Net 0 0 0
    Common Stock 0.016 0.007 0.004 0 0.058
    Additional Paid-In Capital 457.73 436.535 426.426 418.39 413.304
    Retained Earnings (Accumulated Deficit) -446.91 -433.511 -425.27 -414.383 -401.749
    Other Equity, Total 0 1.218 1.387
    Total Liabilities & Shareholders’ Equity 21.981 12.105 23.229 23.991 31.615
    Total Common Shares Outstanding 15.51 6.74903 3.88059 0.29661 0.11565
    Property/Plant/Equipment, Total - Gross 3.233 3.843 3.981 0
    Accrued Expenses 1.529 1.137 2.973 0
    Other Current Liabilities, Total 0.122 0.023 0.006 0.58
    Prepaid Expenses 1.317 0.77 0.813
    Accumulated Depreciation, Total -1.415 -1.387 -1.021
    Accounts Payable 2.611 0.789 0.327
    Capital Lease Obligations 0 0.008
    Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
    Total Current Assets 22.104 19.724 22.097 18.001 15.446
    Cash and Short Term Investments 21.239 18.4 21.28 17.161 14.447
    Cash & Equivalents 21.239 18.4 21.28 17.161 14.447
    Other Current Assets, Total 0.865 1.324 0.817 0.84 0.999
    Total Assets 24.516 21.981 24.75 20.834 18.336
    Property/Plant/Equipment, Total - Net 1.874 1.818 2.205 2.376 2.425
    Goodwill, Net 0.372 0.372 0.372 0.372 0.372
    Intangibles, Net 0.15 0.051 0.06 0.069 0.077
    Other Long Term Assets, Total 0.016 0.016 0.016 0.016 0.016
    Total Current Liabilities 4.921 5.87 9.488 8.354 8.315
    Payable/Accrued 3.203 4.151 2.63 1.609 1.713
    Accrued Expenses 0.11 0.111 0.106 0.127 0.113
    Notes Payable/Short Term Debt 1.608 1.608 6.752 6.618 6.486
    Current Port. of LT Debt/Capital Leases 0 0.003
    Total Liabilities 9.874 11.145 9.995 8.889 8.823
    Total Long Term Debt 4.718 5.005 0 0 0
    Capital Lease Obligations 0
    Other Liabilities, Total 0.235 0.27 0.507 0.535 0.508
    Total Equity 14.642 10.836 14.755 11.945 9.513
    Preferred Stock - Non Redeemable, Net 0 0 0
    Common Stock 0.022 0.016 0.015 0.012 0.01
    Additional Paid-In Capital 465.646 457.73 457.495 450.964 445.734
    Retained Earnings (Accumulated Deficit) -451.026 -446.91 -442.755 -439.031 -436.231
    Total Liabilities & Shareholders’ Equity 24.516 21.981 24.75 20.834 18.336
    Total Common Shares Outstanding 22.1976 15.51 15.36 12.0875 10.1805
    Long Term Debt 4.718 5.005
    • Annual
    • Quarterly
    2021 2020 2019 2018 2017
    Net income/Starting Line -13.399 -8.241 -10.887 -12.634 -22.686
    Cash From Operating Activities -10.28 -8.434 -5.906 -11.975 -18.128
    Cash From Operating Activities 0.395 0.366 0.896 2.004 2.151
    Non-Cash Items 1.486 -0.678 5.023 -0.313 3.444
    Cash Interest Paid 0.388 0.567 1.188 1.331 1.364
    Changes in Working Capital 1.238 0.119 -0.938 -1.032 -1.037
    Cash From Investing Activities -0.082 -0.493 5.57 -0.133 -1.383
    Capital Expenditures -0.144 -0.493 -0.067 -0.133 -1.496
    Other Investing Cash Flow Items, Total 0.062 0 5.637 0 0.113
    Cash From Financing Activities 20.416 -0.319 12.631 7.168 16.815
    Financing Cash Flow Items 0 -1.598 -2.078
    Total Cash Dividends Paid
    Issuance (Retirement) of Stock, Net 20.692 5.105 16.454 8.766 23.613
    Issuance (Retirement) of Debt, Net -0.276 -5.424 -3.823 0 -4.72
    Foreign Exchange Effects 0 -0.004 0.016 0.011
    Net Change in Cash 10.054 -9.246 12.291 -4.924 -2.685
    Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
    Net income/Starting Line -4.116 -13.399 -9.244 -5.52 -2.72
    Cash From Operating Activities -3.876 -10.28 -7.656 -5.405 -3.006
    Cash From Operating Activities 0.147 0.395 0.266 0.179 0.088
    Non-Cash Items 0.284 1.486 0.892 0.53 0.257
    Cash Interest Paid 0.087 0.388 0.292 0.29 0.096
    Changes in Working Capital -0.191 1.238 0.43 -0.594 -0.631
    Cash From Investing Activities -0.577 -0.082 -0.084 -0.08 -0.084
    Capital Expenditures -0.327 -0.144 -0.134 -0.08 -0.084
    Cash From Financing Activities 7.292 20.416 20.674 14.3 9.191
    Issuance (Retirement) of Stock, Net 7.694 20.692 20.682 14.308 9.197
    Issuance (Retirement) of Debt, Net -0.402 -0.276 -0.008 -0.008 -0.006
    Net Change in Cash 2.839 10.054 12.934 8.815 6.101
    Other Investing Cash Flow Items, Total -0.25 0.062 0.05
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 3.0859 1092953 385 2022-12-31 LOW
    Parkman Healthcare Partners LLC Hedge Fund 1.6474 583467 -741558 2022-12-31 MED
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.7286 258052 -385 2022-12-31 LOW
    Schonfeld Strategic Advisors LLC Hedge Fund 0.5376 190400 190400 2022-12-31 HIGH
    Millennium Management LLC Hedge Fund 0.3865 136903 124500 2022-12-31 HIGH
    BlackRock Institutional Trust Company, N.A. Investment Advisor 0.2948 104427 0 2022-12-31 LOW
    Two Sigma Investments, LP Hedge Fund 0.2376 84147 -22260 2022-12-31 HIGH
    Renaissance Technologies LLC Hedge Fund 0.2213 78370 7470 2022-12-31 HIGH
    Petersen (Gregory B) Individual Investor 0.1765 62500 0 2023-02-23 LOW
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.0972 34414 0 2022-12-31 LOW
    Great Valley Advisor Group, Inc. Investment Advisor 0.0949 33600 0 2022-12-31 MED
    Hedrick (Marc H) Individual Investor 0.0948 33580 0 2023-02-23 LOW
    Creative Planning, Inc. Investment Advisor/Hedge Fund 0.0947 33539 0 2022-12-31 LOW
    Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 0.0906 32089 0 2022-12-31 LOW
    B. Riley Wealth Advisors, Inc. Investment Advisor 0.0706 25001 25001 2022-12-31 MED
    UBS Financial Services, Inc. Investment Advisor 0.0537 19003 2795 2022-12-31 LOW
    Clowes (Howard) Individual Investor 0.0508 18000 0 2023-02-23 MED
    Virtu Americas LLC Research Firm 0.0385 13647 13647 2022-12-31 HIGH
    Sims Andrew (John Hugh MacIntyre) Individual Investor 0.0345 12230 0 2023-02-23 LOW
    Warberg Asset Management LLC Hedge Fund 0.0282 10000 0 2022-12-31 HIGH

    Start a global, multi-asset portfolio with an award-winning platform

    Trade now Desktop

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results
    Profit/Loss

    Cytori Therapeutics Company profile

    About Plus Therapeutics Inc

    Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing treatments for patients battling cancer. The Company provides nanotechnology platform to reformulate and improve workhorse chemotherapeutics to provide benefits to patients and healthcare providers. The Company is focused on developing generic oncology drugs that address unmet medical and market needs. The Company’s lead product candidate, DocePLUS, is an albumin-stabilized PEGylated liposomal formulation of docetaxel. DocePLUS is developed for the treatment of patients with small cell lung cancer (SCLC). The Company is also developing DoxoPLUS, which is a generic PEGylated liposomal formulation of doxorubicin. DoxoPLUS is developed for the treatment of breast cancer, ovarian cancer, multiple myeloma and Kaposi’s sarcoma. The Company also focuses on developing Rhenium-186 NanoLiposome (186RNL) for the treatment of recurrent glioblastoma-a rare, incurable and fatal disease.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Plus Therapeutics Inc revenues decreased from $303K to $0K. Net loss increased 63% to $13.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase of 97% to $5.2M (expense), Change in fair value of liability instru decrease of 100% to $6K (income).

    Equity composition

    Common Stock $.001 Par, 02/11, 95M auth., 51,963,679 issd. Insiders own 14.62% IPO:N/A. 05/16, 1-for-15 reverse stock split.

    Industry: Biotechnology & Medical Research (NEC)

    4200 Marathon Blvd Ste 200
    78756-3433

    Income Statement

    • Annual
    • Quarterly

    News

    A file photo shows a part of a stack of 500 Canadian gold coins, worth $1 million USD according to Sprott Money, is displayed at the precious metals dealer's booth at the Prospectors and Developers Association of Canada (PDAC) annual conference in Toronto

    PRECIOUS-Fed slowdown bets steer gold toward second quarterly rise

    Gold prices slipped on Friday, but the safe-haven metal was bound for its second straight quarterly rise after recent banking turmoil raised hopes of a less-aggressive U.S. Federal Reserve and shored up interest in bullion.

    09:37, 31 March 2023
    People use DBS automated teller machines (ATMs) in Singapore March 31, 2022.

    Singapore's DBS has seen inflows in SVB aftermath, CEO says

    DBS Group, Singapore's largest bank, has benefited from inflows amounting to a "few hundred millions" in the aftermath of the collapse of Silicon Valley Bank, its chief executive said on Friday.

    09:24, 31 March 2023
    Traders work on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., March 29, 2023.

    US STOCKS-Futures muted as investors await key inflation data

    U.S. stock index futures were flat on Friday as investors steered clear of big bets ahead of crucial inflation data, amid receding fears of a banking crisis.

    09:16, 31 March 2023
    A file photo of the logo of Australian energy company Origin pictured in Melbourne, Australia, July 3, 2016

    Asia M&As drop to decade low as tumultuous backdrop deters dealmaking

    Mergers and acquisitions (M&A) in the Asia-Pacific region fell to a decade low in the first three months of this year as a tumultuous geopolitical and macroeconomic environment left dealmakers cautious.

    09:14, 31 March 2023
    A file photo of a worker shoveling coal in a supply truck at a yard on the outskirts of Ahmedabad, India, October 25, 2018.

    Coal India surpasses annual output target for first time in 17 years

    Coal India Ltd said on Friday it had breached its annual production target of 700 million tonnes, the first time it had surpassed its goal since the fiscal year that ended in March 2006.

    09:13, 31 March 2023
    A file photo of bull and bear symbols in front of the German stock exchange in Frankfurt, Germany, February 12, 2019.

    Global IPOs marred by banks and recession enjoy few bright spots

    A banking crisis and worries of a recession have dampened the outlook for initial public offerings (IPOs) this year, prompting companies to slow down their plans to go public in what is likely to result in lower fees for investment banks.

    09:06, 31 March 2023
    A file photo of Unicredit Bank logo seen in this illustration taken March 12, 2023.

    UniCredit shareholders gather to vote on CEO's new pay scheme

    Shareholders in UniCredit met on Friday to vote on a new pay scheme for Chief Executive Andrea Orcel designed to reward outperformance with a 30% pay raise.

    09:04, 31 March 2023

    People also watch

    Natural Gas

    2.11 Price
    -0.570% 1D Chg, %
    Long position overnight fee -0.4392%
    Short position overnight fee 0.4173%
    Overnight fee time 21:00 (UTC)
    Spread 0.005

    Oil - Crude

    74.89 Price
    +0.700% 1D Chg, %
    Long position overnight fee -0.0170%
    Short position overnight fee -0.0049%
    Overnight fee time 21:00 (UTC)
    Spread 0.03

    BTC/USD

    27,949.55 Price
    -0.650% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 60.00

    Gold

    1,980.12 Price
    -0.010% 1D Chg, %
    Long position overnight fee -0.0180%
    Short position overnight fee 0.0098%
    Overnight fee time 21:00 (UTC)
    Spread 0.30

    Still looking for a broker you can trust?

    Join the 500.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading